256 related articles for article (PubMed ID: 23002953)
1. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
2. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
3. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
Price ER; Brooks JD; Watson EJ; Brennan SB; Comen EA; Morris EA
Eur Radiol; 2014 Jan; 24(1):162-8. PubMed ID: 23982290
[TBL] [Abstract][Full Text] [Related]
4. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.
King V; Gu Y; Kaplan JB; Brooks JD; Pike MC; Morris EA
Eur Radiol; 2012 Dec; 22(12):2641-7. PubMed ID: 22752463
[TBL] [Abstract][Full Text] [Related]
5. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
[TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
[TBL] [Abstract][Full Text] [Related]
7. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
8. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
10. Background parenchymal enhancement at breast MR imaging and breast cancer risk.
King V; Brooks JD; Bernstein JL; Reiner AS; Pike MC; Morris EA
Radiology; 2011 Jul; 260(1):50-60. PubMed ID: 21493794
[TBL] [Abstract][Full Text] [Related]
11. Mammographic density, MRI background parenchymal enhancement and breast cancer risk.
Pike MC; Pearce CL
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii37-viii41. PubMed ID: 24131968
[TBL] [Abstract][Full Text] [Related]
12. Impact of fibroglandular tissue and background parenchymal enhancement on diffusion weighted imaging of breast lesions.
Iacconi C; Thakur SB; Dershaw DD; Brooks J; Fry CW; Morris EA
Eur J Radiol; 2014 Dec; 83(12):2137-2143. PubMed ID: 25445896
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
[TBL] [Abstract][Full Text] [Related]
14. MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
Bennani-Baiti B; Dietzel M; Baltzer PA
PLoS One; 2016; 11(7):e0158573. PubMed ID: 27379395
[TBL] [Abstract][Full Text] [Related]
15. Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?
Dontchos BN; Rahbar H; Partridge SC; Korde LA; Lam DL; Scheel JR; Peacock S; Lehman CD
Radiology; 2015 Aug; 276(2):371-80. PubMed ID: 25965809
[TBL] [Abstract][Full Text] [Related]
16. Fully automatic quantification of fibroglandular tissue and background parenchymal enhancement with accurate implementation for axial and sagittal breast MRI protocols.
Wei D; Jahani N; Cohen E; Weinstein S; Hsieh MK; Pantalone L; Kontos D
Med Phys; 2021 Jan; 48(1):238-252. PubMed ID: 33150617
[TBL] [Abstract][Full Text] [Related]
17. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
18. Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training.
Melsaether A; McDermott M; Gupta D; Pysarenko K; Shaylor SD; Moy L
AJR Am J Roentgenol; 2014 Jul; 203(1):209-15. PubMed ID: 24951217
[TBL] [Abstract][Full Text] [Related]
19. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cyst formation in patients using tamoxifen for breast cancer.
Metindir J; Aslan S; Bilir G
Jpn J Clin Oncol; 2005 Oct; 35(10):607-11. PubMed ID: 16254040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
